Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of Her-2/neu Status in Carcinomas With Amplified Chromosome 17 Centromere Locus

1 Nov 2006

Abstract excerpt

Accurate assessment of Her-2/neu (erb-b2) status in breast carcinoma is essential for therapy planning. Clinical assays are targeted at protein overexpression (immunohistochemical analysis) or gene amplification (fluorescence in situ hybridization [FISH]). Cases with aberrant FISH signal patterns are problematic and may lead to underreporting of Her-2/neu amplification. We performed FISH with additional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to HER2/EGFR in Cancer Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17050068
DOI: 10.1309/9eym6ve58f2ycd9f

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of Her-2/neu Status in Carcinomas With Amplified Chromosome 17 Centromere LocusPMID 17050068Read ↗

Determining True <i>HER2</i> Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-<i>HER2</i> Targeted TherapySemantic proximity Read ↗

Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.Semantic proximity Read ↗

Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancerSemantic proximity Read ↗

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.Semantic proximity Read ↗

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily PracticeSemantic proximity Read ↗

Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.Semantic proximity Read ↗

Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort studySemantic proximity Read ↗

Association of <i>HER-2</i> Copy Number and <i>HER-2/CEP-17</i> Ratio with Neoadjuvant Taxane-Containing Chemotherapy Sensitivity in Locally Advanced Breast CancerSemantic proximity Read ↗

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistrySemantic proximity Read ↗

Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma: Implications for Clinical HER2 Testing and InterpretationSemantic proximity Read ↗

Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in the Determination of HER2 Status in Breast CancerSemantic proximity Read ↗

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.